All News
Filter News
Found 115 articles
-
Ipsen appoints Mari Scheiffele as EVP and President, Specialty Care International
10/11/2021
Ipsen announced the appointment of Mari Scheiffele as EVP and President, Specialty Care International, effective November 1st 2021.
-
The company also reported on its COVID-19 vaccine production with CureVac, a drug it is abandoning, and a few specific drug updates.
-
BioSpace takes an in-depth look at the Top 25 of Q1. You should be aware of these biopharma companies as they hold a great future ahead. So, check them out.
-
What makes this particularly surprising is that in July 2020, mirikizumab hit all primary endpoints against placebo and secondary endpoints against Novartis’ Cosentyx in a Phase III OASIS-2 study of plaque psoriasis.
-
Ipsen Appoints Gwenan White as Executive Vice President, Communications and Public Affairs
1/20/2021
Ipsen announced the appointment of Gwenan White as Executive Vice President, Communications and Public Affairs, effective March 2021.
-
Biogen successfully fended off a patent challenge from generic company Mylan over its multiple sclerosis (MS) drug Tecfidera.
-
I Have a Dream… Five Dreams for Biotech
1/20/2020
Here are five “dreams” that patients are hoping will come to fruition. -
Clinical Catch-Up: January 13-17
1/20/2020
There were plenty of clinical trial announcements this week. Here's a look. -
Here’s a look at the top 10 companies noted in the BioSpace Ideal Employer 2019 survey for being the most innovative and what they’ve been up to recently.
-
Similar to the Biotech Bay list, BioSpace takes a look at the top 10 2019 Life Sciences Ideal Employer Report’s for Genetown.
-
Unfortunately, this makes Amgen yet another major biopharma company to exit or slim down work on neurological diseases. Others include Pfizer, Bristol-Myers Squibb, GlaxoSmithKline and AstraZeneca.
-
Clinical Catch-Up: October 28-Nov 1
11/4/2019
Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look. -
NetNoggin® releases exploratory analysis "Alzheimer's Recent Drug Failures"
10/2/2019
NetNoggin® analyzes big data to better understand why Alzheimer's drugs fail clinical trials and how the Alzheimer's community reacts to the failures.
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
BridgeBio launched Charlotte, N.C.-based ML Bio Solutions to develop the LGMD2i asset BBP-418, a substrate supplementation therapy.
-
According to the U.S. Centers for Disease Control and Prevention, about 2 million people each year are infected with antibiotic-resistant bacteria and 23,000 people die as a result. A recent study by the UK government estimated that by 2050, as many as 10 million people could die worldwide from a...
-
There’s clearly a need for new antibiotics to fight infections. If so, why are so many companies in the space abandoning it or going out of business?
-
Clinical Catch-Up for July 8-12
7/15/2019
It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look. -
Earlier this week, Biogen reported out its first-quarter financial results, showing an 11% increase in revenues, hitting $3.5 billion. But in light of the company’s announcement in late March that it was dropping development of aducanumab for Alzheimer’s, analysts are speculating on what the comp...
-
Blackstone Life Sciences, a private investment firm, along with Novartis, launched Anthos Therapeutics with a $250 million investment. Anthos will be headquartered in Cambridge, Mass.